{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:03Z","timestamp":1790661063266,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jconrel.2024.12.049","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T19:32:03Z","timestamp":1736019123000},"page":"982-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nasal absorption of oxycodone predicted using a novel computational fluid dynamics-physiologically based pharmacokinetic model"],"prefix":"10.1016","volume":"378","author":[{"given":"Ross L.","family":"Walenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Babiskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid S.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.12.049_bb0005","author":"Basics About Presciption Opioids"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0010","series-title":"Drug Overdose Deaths in the United States, 2001\u20132021","author":"Spencer","year":"2022"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/03007995.2017.1419171","article-title":"Abuse-deterrent opioids: an update on current approaches and considerations","volume":"34","author":"Pergolizzi","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17425255.2018.1546289","article-title":"Safety and performance of current abuse-deterrent formulations","volume":"14","author":"Ahmad","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/pmt-2015-0005","article-title":"Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain","volume":"6","author":"Hale","year":"2016","journal-title":"Pain Manag."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","article-title":"Abuse-deterrent opioid formulations","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0035","series-title":"Guidance for Industry: Abuse-Deterrent Opioids \u2013 Evaluation and Labeling","year":"2015"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0045","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/17425247.2016.1211638","article-title":"Crush resistance and insufflation potential of poly (ethylene oxide)-based abuse deterrent formulations","volume":"13","author":"Muppalaneni","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0050","series-title":"Draft Guidance on Oxycodone Hydrochloride","year":"2018"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0055","series-title":"Guidance for Industry: General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products","year":"2017"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0060","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/cts.13053","article-title":"Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users","volume":"14","author":"Raofi","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0065","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11095-021-03066-0","article-title":"Preferential oxycodone loss of physically manipulated abuse deterrent oxycodone HCl extended release tablets prepared for nasal insufflation studies","volume":"38","author":"Meng","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaerosci.2013.12.008","article-title":"CFD simulation of total and regional fiber deposition in human nasal cavities","volume":"69","author":"Dastan","year":"2014","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1006\/rtph.2002.1576","article-title":"Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate","volume":"36","author":"Andersen","year":"2002","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/jamp.2015.1252","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: development of a CFD model","volume":"29","author":"Rygg","year":"2016","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1595-5","article-title":"Assessing drug release from manipulated abuse deterrent formulations","volume":"21","author":"Feng","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0100","series-title":"Respiratory Drug Delivery 2016","first-page":"617","article-title":"Comparison of the in vitro deposition of Nasonex\u00ae nasal spray product in two realistic nasal airway models","author":"Azimi","year":"2016"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaerosci.2014.08.003","article-title":"Variability in nose-to-lung aerosol delivery","volume":"78","author":"Walenga","year":"2014","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0110","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1152\/japplphysiol.01233.2007","article-title":"Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways","volume":"104","author":"Xi","year":"2008","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/chemse\/25.1.1","article-title":"Sniffing longer rather than stronger to maintain olfactory detection threshold","volume":"25","author":"Sobel","year":"2000","journal-title":"Chem. Senses"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1208\/s12249-020-01804-y","article-title":"Use of drug release testing to evaluate the retention of abuse-deterrent properties of polyethylene oxide matrix tablets","volume":"21","author":"Meruva","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0125","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.xphs.2016.03.033","article-title":"Linking suspension nasal spray drug deposition patterns to pharmacokinetic profiles","volume":"105","author":"Rygg","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11095-015-1837-5","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: effects of nasal spray suspension particle size and properties","volume":"33","author":"Rygg","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2013possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0145","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/02786820300906","article-title":"Aerosol deposition in the extrathoracic region","volume":"37","author":"Cheng","year":"2003","journal-title":"Aerosol Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2017.1436","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic modeling accurately predicts the better bronchodilatory effect of inhaled versus oral salbutamol dosage forms","volume":"32","author":"Boger","year":"2019","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0160","series-title":"GastroPlus\u2122 User's Manual","year":"2021"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/08958370701864235","article-title":"Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein","volume":"20","author":"Schroeter","year":"2008","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0175","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00007691-199310000-00014","article-title":"Determination of the serum protein binding of oxycodone and morphine using ultrafiltration","volume":"15","author":"Leow","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5055\/jom.2012.0112","article-title":"Interpretation of oxycodone concentrations in oral fluid","volume":"8","author":"Moore","year":"2012","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MJT.0b013e3182456d9b","article-title":"A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-A with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions","volume":"21","author":"Leibowitz","year":"2014","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0190","series-title":"Application Number: 22-272. Clinical Pharmacology and Biopharmaceutics Review(s)","year":"2010"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0195","series-title":"OXYCONTIN\u00ae (Oxycodone Hydrochloride) Extended-Release Tablets, for Oral Use","year":"2010"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0200","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40261-017-0561-9","article-title":"In vitro drug release after crushing: evaluation of Xtampza\u00ae ER and other ER opioid formulations","volume":"37","author":"Mayock","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/aic.690200329","article-title":"Prediction of diffusion coefficients for nonelectrolytes in dilute aqueous solutions","volume":"20","author":"Hayduk","year":"1974","journal-title":"AICHE J."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0210","series-title":"Verification and Validation in Computational Modeling of Medical Devices","author":"American Society of Mechanical Engineers","year":"2018"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/08942680152484199","article-title":"Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway","volume":"14","author":"Cheng","year":"2001","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","article-title":"Evaluation of the clearance characteristics of bioadhesive systems in humans","volume":"178","author":"Soane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124660","article-title":"CFD-PK model for nasal suspension sprays: validation with human adult in vivo data for triamcinolone acetonide","volume":"665","author":"Dutta","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0230","series-title":"Evaluating the Abuse Potential of Extended-Release Polyethylene Oxide Matrix Tablets","author":"Rezaei","year":"2023"},{"key":"10.1016\/j.jconrel.2024.12.049_bb0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Behl","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.12.049_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2021.105757","article-title":"Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake","volume":"155","author":"Chari","year":"2021","journal-title":"J. Aerosol Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924009040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924009040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:47:19Z","timestamp":1778244439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924009040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"alternative-id":["S0168365924009040"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal absorption of oxycodone predicted using a novel computational fluid dynamics-physiologically based pharmacokinetic model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}